In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. Objectives: BAL4815 is the active component of the antifungal triazole agent BAL8557 (the water-soluble prodrug). We compared the in vitro activity of BAL4815 with that of itraconazole, voriconazole, caspofungin and amphotericin B against 118 isolates of Aspergillus comprising four different species (fumigatus, terreus, flavus and niger); the isolates were pre-selected to include 16 isolates demonstrating in vitro resistance to other agents.
Introduction
Despite advances in antifungal therapy, mortality rates following invasive aspergillosis remain unacceptably high. 1 For many years amphotericin B has been the bedrock of systemic antifungal therapy and concerns about its toxicity have been partially addressed by the introduction of lipid formulations, but significant toxicity still remains often leading to withdrawal of therapy. 2 The introduction of the echinocandins has been welcomed as they have an alternative target compared with other antifungal agents but the mechanism of action against Aspergillus is predominantly fungistatic and this is less than ideal in neutropenic patients.
Since the discovery of the antifungal activity of the first azoles 60 years ago, enormous advances have been made in the group to reduce toxicity, enhance bioavailability, improve the antifungal spectrum and counteract resistance. It is hoped that with the introduction of the second-generation triazoles many of the shortcomings of earlier azoles have been eliminated. Voriconazole in a large randomized control trial in patients with aspergillosis demonstrated superiority to amphotericin in terms of both response and survival. 4 However, voriconazole still has some drawbacks, including dose-related visual disturbances, non-linear pharmacokinetics and high inter-individual variability of pharmacokinetics. Cyclodextrin in the intravenous formulation also complicates treatment of patients with significant renal dysfunction.
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BAL4815 is the active antifungal component of BAL8557 (the water-soluble precursor, suitable for oral and intravenous delivery) and is of the triazole class of agents ( Figure 1) . We compared the in vitro activity of BAL4815 with that of itraconazole, voriconazole, caspofungin and amphotericin B against 118 isolates of Aspergillus comprising four different species ( fumigatus, terreus, flavus and niger); the isolates were pre-selected to include 16 isolates demonstrating resistance to itraconazole, amphotericin B or caspofungin. 
Materials and methods

Organisms
Susceptibility tests were performed on 118 clinical Aspergillus isolates comprising 62 Aspergillus fumigatus isolates, 20 Aspergillus flavus isolates and 18 isolates each of Aspergillus niger and Aspergillus terreus. Sixteen A. fumigatus isolates were resistant to itraconazole, caspofungin or amphotericin B (some also had increased MICs of posaconazole). 6 Isolates for which the MICs of itraconazole, voriconazole, caspofungin and amphotericin B are known (Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019) were included as quality control strains for susceptibility testing.
7 All cultures were cultivated from frozen stock on Sabouraud dextrose agar (SAB) (Oxoid, Basingstoke, UK).
Antifungal agents
BAL4815 (Basilea Pharmaceutica, Basel, Switzerland) was provided as a pure powder by the manufacturer. Itraconazole (Janssen Pharmaceuticals, Beerse, Belgium) and amphotericin B (Sigma, Poole, UK) were obtained as pure compounds. Voriconazole (Pfizer Ltd Sandwich, UK) and caspofungin (Merck Sharp & Dohme Ltd, Hoddesdon UK) were obtained in vials for intravenous administration.
Stock solutions (3200 mg/L) of all drugs were prepared using appropriate solvents-voriconazole and caspofungin (sterile distilled water); BAL4518, itraconazole and amphotericin B (dimethyl sulphoxide)-and adjusted for potency when necessary. Each aliquot was then dispensed in further aliquots and stored in glass vials, protected from the light, at -20 C until required.
Susceptibility testing
Susceptibility tests were performed according to the broth microdilution modified method of the NCCLS M38-A accepted standard using RPMI 1640 medium (Sigma) buffered to pH 7.0 with MOPS (Sigma).
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In brief, final drug ranges (in mg/L) were 0.0078-8 for BAL4815, voriconazole and itraconazole, and 0.0156-4 for caspofungin and amphotericin B. Inoculum suspensions were prepared from 5-8 day cultures grown on SAB at 37 C and adjusted using a counting chamber. The final inoculum was between 0.5 · 10 4 and 5 · 10 4 cfu/mL as demonstrated by quantitative colony counts. Drug-free and cell-free controls were included. BAL4815, itraconazole, voriconazole and amphotericin B microdilution plates were incubated in air; caspofungin microdilution plates were incubated in 1% O 2 /5% CO 2 /94% N 2 to aid reading. 8 Readings were made after 48 h of incubation at 37 C (the Candida control strains were examined at 24 h). The MIC endpoints for BAL4815, itraconazole, voriconazole and amphotericin B were read visually as the lowest drug concentration that prevented any discernible growth. The MIC endpoints for caspofungin were read visually and taken as that which reduced growth by 80% compared with the drug-free control.
Minimum fungicidal concentrations (MFCs) were also determined for all drugs (other than caspofungin). For each isolate, 100 mL was removed from all wells without visible growth. Each aliquot was spot inoculated onto SAB plates, and the liquid was allowed to soak into the agar. When dry, the plate was streaked to separate any conidia and to remove them from the drug source. The plates were incubated at 37 C for 48 h. The MFC was defined as the lowest drug concentration that allowed the growth of 50 or fewer colonies (99% kill).
Twenty percent of the isolates (24 of 118) were randomly selected and retested against each drug to assess the reproducibility of the method. In all cases wherein there was a discrepancy tests were repeated a third time before values were assigned.
The differences between species were analysed using the Kruskal-Wallis test for multiple comparisons using the computer package StatsDirect (Ashwell, Herts, UK).
Results
Summaries of in vitro susceptibility values for the 118 isolates are shown in Table 1 0 and 4.0) . With respect to MFCs, isolates of A. terreus were significantly less susceptible to BAL4815 than A. fumigatus, A. flavus and A. niger (P < 0.0001, P < 0.0002 and P = 0.0287, respectively).
The MFC value was the same as or only one well higher than the MIC for 63%, 51% and 44% of isolates tested using BAL4815, itraconazole and voriconazole, respectively (the strains resistant to itraconazole were not used in the analysis of the itraconazole data for this comparison).
The reproducibility study on 20% of the isolates showed that 87.5%, 87.5%, 87.5%, 91.7% and 95.8% of isolates retested were within one well of the original MIC value of BAL4815, itraconazole, voriconazole, caspofungin and amphotericin B, respectively.
Discussion
This study demonstrates that in vitro testing of BAL4815 is possible with reproducible endpoints using the general recommendations of the NCCLS 38A document. 7 The study further demonstrates that BAL4815 has potent in vitro antifungal activity against all four Aspergillus species including strains resistant to itraconazole, caspofungin or amphotericin B. The GM and range of MICs of BAL4815 are similar to those of itraconazole and voriconazole and are generally within the achievable range demonstrated in single and multiple dose human pharmacokinetic studies. 9 This study further demonstrated that BAL4815 showed primary fungicidal activity (MFC within two dilutions of the MIC) against all four Aspergillus species and that for 63% of isolates the MFC was within one well of the MIC, superior to itraconazole or voriconazole. Indeed 68% of isolates were killed at £2.0 mg/L against BAL4815, compared with 51% against itraconazole and 92% against voriconazole. In this study 14 isolates were selected with MICs of itraconazole of ‡8 mg/L; the GM MIC and MFC for these strains of BAL4815 were 1.1 and 2.3 mg/L, respectively. Many of these strains had previously also demonstrated increased MICs and MFCs of posaconazole. 6 Although these values are 2-fold higher than the GMs for the total data set they are still within the expected therapeutic range of the compound. If the itraconazole-resistant strains had not been pre-selected and only more 'typical' strains included, the GM MICs and MFCs would be 0.56 and 1.57 mg/L, 0.25 and 1.34 mg/L, and 0.33 and 0.97 mg/L for BAL4815, itraconazole and voriconazole, respectively. BAL8557 is a prodrug, which is rapidly cleaved into the active component (BAL4815) and an inactive prodrug cleavage product (BAL8728) after oral or intravenous administration. The conversion is rapid and complete with very low levels of the cleavage product detectable in the serum after oral or intravenous administration. In humans the serum beta phase half-life is long (85-117 h) and the AUC 0-24 14-40 mg · h/mL (50-100 mg/day) demonstrates high levels of drug exposure. With such rapid conversion of a water-soluble prodrug, addition of potentially toxic cyclodextrin to increase/achieve solubility as occurs in itraconazole and voriconazole intravenous solutions is not required for this new azole.
There is currently little data available on the likely pharmacodynamic drivers of azoles against infections caused by Aspergillus. Recent murine Candida pharmacodynamic models have indicated that the pharmacodynamic driver most likely to predict the outcome of azoles is the AUC/MIC ratio 10 in agreement with a murine model of candidiasis with BAL8557. 11 The GM MIC of BAL4815 for Aspergillus strains was 0.62 mg/L with an average AUC/MIC ratio in the range 23.3-66.7 after treatment with 50-100 mg/day. The AUC/MIC ratio required to predict success of therapy has not yet been established for Aspergillus infections but in Candida infections target ratios of free drug in excess of 20-25 are associated with treatment efficacy (in experimental in vivo models). 12 Such large AUC/MIC ratios might not be necessary in Aspergillus therapy; preliminary encouraging results from an in vivo efficacy study in mice were observed with BAL4815 levels above but close to the MIC. 13 Therefore it seems probable that after treatment with BAL8557 there will be sufficient exposure to BAL4815 to have a favourable outcome.
BAL4815 demonstrates promising antifungal activity in vitro warranting further in vivo investigation. Additionally at the doses evaluated in Phase I studies, efficacy against invasive aspergillosis is probable after either oral or intravenous administration. BAL4815 is now entering Phase III clinical trials.
